Subject expert committee nod to Bharat Biotech ’s intranasal vaccine trials

The company had sought permission to conduct both phase-I and phase-II trials. “However, the SEC has asked the company to present data of phase-I trials first, after which permission for phase-II trials would be considered,” one of the persons told ET on condition of anonymity.
Source: The Economic Times - Category: Consumer Health News Source Type: news